Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab‐naïve relapsed multiple myeloma
European Journal of Haematology · 2024
DOI: 10.1111/ejh.14193 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Danai Dima und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology/Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Antibodies, Monoclonal. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
Objectives and Methods We conducted a multicenter retrospective study to analyze the safety and efficacy of DPd versus DKd in daratumumab naïve RRMM patients treated in real‐world practice.
Results
A total of 187 patients with RRMM were included in the analysis; 128 patients received DPd, and 59 patients received DKd. A vast majority (80%) of patients had lenalidomide refractory disease and nearly 50% had bortezomib refractory disease. The overall response and complete response rates were 76% and 34% in the DPd group versus 80% and 51% in the DKd group, respectively. With a median follow up of 36 months for the entire patient population, median PFS and OS in the DPd versus DKd groups were 12, 12, 37, and 35 months, respectively. The most common grade 3+ adverse events in the DPd versus DKd groups were neutropenia (32% vs. 7%), anemia (14% vs. 10%), thrombocytopenia (13% vs. 15%), and cardiovascular events (4% vs. 15%), respectively. Both DPd and DKd appeared to be a safe and effective treatment options for RRMM.
Conclusions
While there were more cytopenias associated with DPd and more cardiovascular side effects with DKd, there were no significant differences in the survival outcomes with these two regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology/Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, USA.
- US Myeloma Innovations Research Collaborative (USMIRC), Westwood, Kansas, USA.
- Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas, USA.
- Division of Hematology/Oncology, Medical University of South Carolina, Charleston, South Carolina, USA.
- Medical University of South Carolina School of Medicine, Charleston, South Carolina, USA.
- University of Kansas School of Medicine, Kansas City, Kansas, USA.
ORCID-Profile: Hamza Hashmi
Zitieren
APA
Dima, D., Mansour, R., Davis, J. A., Minchak, M., Goel, U., Atallah, R., Logan, E., Tabak, C., Rashid, A., Ahmed, N., Abdallah, A. O., & Hashmi, H. (2024). Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab‐naïve relapsed multiple myeloma. European Journal of Haematology. https://doi.org/10.1111/ejh.14193
Vancouver
Dima D, Mansour R, Davis JA, Minchak M, Goel U, Atallah R, et al. Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab‐naïve relapsed multiple myeloma. European Journal of Haematology. 2024. doi:10.1111/ejh.14193
BibTeX
@article{Dima2024,
author = {Dima, Danai and Mansour, Razan and Davis, James A and Minchak, Megan and Goel, Utkarsh and Atallah, Rawan and Logan, Emerson and Tabak, Carine and Rashid, Aliya and Ahmed, Nausheen and Abdallah, Al-Ola and Hashmi, Hamza},
title = {Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab‐naïve relapsed multiple myeloma},
journal = {European Journal of Haematology},
year = {2024},
doi = {10.1111/ejh.14193}
}
EUVIMED